Eloralintide Study for Weight, Diabetes and Heart Risk in Adults
Tests eloralintide against placebo in adults with obesity, diabetes and heart risk.
Plain-language title generated from the registry record
Registry title: A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
Key facts
- Where
- Belagavi, Guntur, Guwahati, Mumbai, Nagpur, Pune, Rishikesh, and Surat, IndiaSee the 8 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 45 to 64 with type 2 diabetes, overweight or obesity, and a higher risk of heart and blood vessel problems.
- Age
- 45 to 64 years
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes with HbA1c between ≥ 6.5% (48 mmol/mol) and ≤ 9.5% (80 mmol/mol), BMI ≥ 25.0 kg/m2, and an increased risk of cardiovascular events.
- Earlier treatment
- On stable treatment with an unchanged dose of at least 1 and no more than 4 antihyperglycemic therapies for at least 90 days before screening. At least one self-reported unsuccessful dietary effort to lose weight.
- Biomarker or test result
- HbA1c between ≥ 6.5% (48 mmol/mol) and ≤ 9.5% (80 mmol/mol) at screening.
Main reasons for not taking part
- Type 1 diabetes
- Prior or planned surgery, endoscopic procedure or device-based therapy for obesity (some exceptions apply)
- New York Heart Association Functional Classification IV congestive heart failure
- Within 60 days before screening: heart attack, stroke, hospitalization for heart failure, or artery revascularization
- Sulfonylurea combined with insulin within 90 days before screening
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 64 years old?
Source: NCT07900633, who can take part
Where in India
- KLES Dr. Prabhakar Kore Hospital & M.R.CBelagavi, IndiaContact: Sanjay Kumar Porwal (principal investigator)No longer taking part
- Endolife Speciality HospitalsGuntur, IndiaContact: Anjith VUPPUTURI (principal investigator)No longer taking part
- Gauhati Medical college and HospitalGuwahati, IndiaContact: Farhin Iqbal (principal investigator)No longer taking part
- King Edward Memorial Hospital & Seth Gordhandas Sunderdas Medical CollegeMumbai, IndiaContact: Charan Lanjewar (principal investigator)No longer taking part
- Kingsway Hospitals (Best Multispeciality Hospital in Nagpur)Nagpur, IndiaContact: Rishi Lohiya (principal investigator)No longer taking part
- Arogyaseva Medical Academy of India - Ace HospitalPune, IndiaContact: Hemant Kokane (principal investigator)No longer taking part
- All India Institute of Medical Sciences, RishikeshRishikesh, IndiaContact: Barun Kumar (principal investigator)No longer taking part
- Nirmal Hospital Pvt Ltd.Surat, IndiaContact: Pritesh Parekh (principal investigator)No longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07900633EU 2026-525919-14-00
- Record updated
- 3 November 2026
- Original description
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overweight, type 2 diabetes, and increased cardiovascular risk.Read full original descriptionShow less
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once-Weekly Eloralintide in Adult Participants With Obesity or Overweight, Type 2 Diabetes, and Increased CV Risk
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overweight, type 2 diabetes, and increased cardiovascular risk.
Inclusion: Have type 2 diabetes; Have a HbA1c value between ≥ 6.5% and ≤ 9.5% at screening; Are on stable treatment with an unchanged dose of at least 1 and no more than 4 antihyperglycemic therapies for at least 90 days before screening; Have an increased risk of cardiovascular events; Have a BMI ≥ 25.0 kg/m2 at screening; Have a stable body weight (<5% body weight change) for 90 days prior to screening; Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have had within 60 days prior to screening:; acute myocardial infarction; stroke; hospitalization for congestive heart failure, or; coronary, peripheral, or carotid artery revascularization procedure; Have received treatment combining sulfonylurea and insulin within 90 days prior to screening; Have type 1 diabetes; Have a history or diagnosis of New York Heart Association Functional Classification IV congestive heart failure.